Terry A. Jacobson

Terry A. Jacobson's AcademicInfluence.com Rankings

Terry A. Jacobson

Engineering

#5341

World Rank

#6593

Historical Rank

Electrical Engineering

#1476

World Rank

#1570

Historical Rank

engineering Degrees

Terry A. Jacobson

Computer Science

#6847

World Rank

#7213

Historical Rank

Computational Linguistics

#1273

World Rank

#1287

Historical Rank

Machine Learning

#2357

World Rank

#2386

Historical Rank

Artificial Intelligence

#2637

World Rank

#2678

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Terry A. Jacobson's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Terry A. Jacobson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Terry A. Jacobson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (2019) (1636)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015) (626)
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015) (587)
Risk for myopathy with statin therapy in high-risk patients. (2003) (467)
Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association (2017) (430)
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. (2006) (427)
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. (2014) (408)
Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. (2012) (391)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. (2015) (388)
An assessment by the Statin Muscle Safety Task Force: 2014 update. (2014) (383)
Safety considerations with fibrate therapy. (2007) (370)
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. (2009) (360)
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019) (346)
Effect of a Pharmacist Intervention on Clinically Important Medication Errors After Hospital Discharge (2012) (293)
Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. (2009) (279)
Statin-induced myopathy: a review and update (2011) (271)
Patient Literacy and Question-asking Behavior During the Medical Encounter: A Mixed-methods Analysis (2007) (264)
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. (2011) (264)
Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis (2011) (254)
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis (2007) (244)
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. (2012) (242)
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. (2004) (238)
Predictors of medication self-management skill in a low-literacy population (2006) (231)
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. (2019) (223)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. (2019) (221)
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018) (221)
Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. (2006) (217)
Development and Psychometric Evaluation of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) in Low-Literacy Patients With Chronic Disease (2007) (209)
The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. (2001) (206)
Development of an illustrated medication schedule as a low-literacy patient education tool. (2007) (206)
Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. (2013) (205)
The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. (2015) (202)
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. (2019) (183)
Safety and efficacy of statin therapy (2018) (180)
Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. (2008) (178)
The importance of non-HDL cholesterol reporting in lipid management. (2008) (166)
Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates. A randomized controlled trial. (1999) (163)
Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. (2008) (158)
Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. (2005) (155)
Hypertriglyceridemia and cardiovascular risk reduction. (2007) (150)
Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) (149)
Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. (2008) (146)
Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. (2011) (146)
Statin safety: lessons from new drug applications for marketed statins. (2006) (143)
An assessment by the Statin Intolerance Panel: 2014 update. (2014) (141)
Statin safety: an assessment using an administrative claims database. (2006) (134)
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. (2014) (133)
Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. (2010) (131)
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. (1990) (126)
30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. (2010) (123)
Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. (2012) (119)
National Lipid Association Annual Summary of Clinical Lipidology 2015. (2014) (116)
Health literacy and the quality of physician-patient communication during hospitalization. (2010) (113)
Effects of niacin on glucose control in patients with dyslipidemia. (2008) (110)
National Lipid Association Annual Summary of Clinical Lipidology 2016. (2016) (107)
Lipoprotein(a), cardiovascular disease, and contemporary management. (2013) (92)
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. (2017) (91)
Fluvastatin with and without niacin for hypercholesterolemia. (1994) (88)
Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. (2016) (84)
Safety considerations with gastrointestinally active lipid-lowering drugs. (2007) (84)
Evidence-Based Management of Statin Myopathy (2010) (84)
Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. (2000) (84)
New perspectives on the management of low levels of high-density lipoprotein cholesterol. (1999) (79)
Flaxseed oil supplementation does not affect plasma lipoprotein concentration or particle size in human subjects. (2006) (79)
Identifying and Assisting Low-Literacy Patients with Medication Use: A Survey of Community Pharmacies (2005) (78)
Managing dyslipidemia in chronic kidney disease. (2008) (78)
NLA Task Force on Statin Safety--2014 update. (2014) (78)
The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability (2017) (75)
Maximizing the cost-effectiveness of lipid-lowering therapy. (1998) (73)
Myopathy with statin–fibrate combination therapy: clinical considerations (2009) (73)
Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. (2019) (68)
Rationale and Design of the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) Study (2010) (68)
The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. (2020) (67)
Improving Medication Adherence through Graphically Enhanced Interventions in Coronary Heart Disease (IMAGE-CHD): A Randomized Controlled Trial (2012) (65)
Low literacy is associated with uncontrolled blood pressure in primary care patients with hypertension and heart disease. (2014) (64)
Secondary prevention of coronary artery disease with omega-3 fatty acids. (2006) (63)
REDUCE-IT USA (2019) (63)
National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. (2019) (62)
Using apolipoprotein B to manage dyslipidemic patients: time for a change? (2010) (60)
Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. (2014) (60)
Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. (2014) (59)
Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial (2016) (58)
Cardiovascular disease prevention counseling in residency: resident and attending physician attitudes and practices. (2004) (57)
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. (2020) (57)
Clinical characterization and molecular mechanisms of statin myopathy (2008) (54)
Fibrates in Combination With Statins in the Management of Dyslipidemia (2006) (53)
The Lower the Better in Hypercholesterolemia Therapy: A Reliable Clinical Guideline? (2000) (52)
Omega-3 Fatty Acids for Cardiovascular Disease Prevention (2010) (50)
Overcoming ‘Ageism’ Bias in the Treatment of Hypercholesterolaemia (2006) (49)
Low-literacy interventions to promote discussion of prostate cancer: a randomized controlled trial. (2007) (48)
Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). (2016) (47)
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. (2017) (45)
Characteristics of US adults with the metabolic syndrome and therapeutic implications (2004) (44)
Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. (2012) (43)
Beyond lipids: The role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease (2007) (43)
Development and Implementation of a Health Literacy Training Program for Medical Residents (2006) (42)
Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. (2014) (42)
Changes in plasma cholesterol levels after hospitalization for acute coronary events. (1996) (40)
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. (2016) (40)
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. (2010) (39)
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. (2011) (38)
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. (2013) (38)
Reduction in Revascularization With Icosapent Ethyl (2020) (36)
New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipid (2015) (35)
Health care providers' training, perceptions, and practices regarding stress and health outcomes. (2003) (35)
Beyond the Mediterranean diet: the role of omega-3 Fatty acids in the prevention of coronary heart disease. (2003) (32)
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. (2019) (31)
Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. (2016) (30)
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia (2015) (30)
Conclusions and recommendations from the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease with n-3 Fatty Acids. (2008) (30)
Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials. (2013) (29)
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. (2021) (29)
Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. (1995) (29)
Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease (2017) (29)
Clinical context: current concepts of coronary heart disease management. (2001) (29)
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. (1994) (28)
Combination lipid-altering therapy: An emerging treatment paradigm for the 21st century (2001) (27)
The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered? (2006) (27)
Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study (2006) (26)
Fluvastatin: clinical and safety profile. (2004) (25)
Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. (2017) (24)
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. (2013) (24)
New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipid (2016) (23)
Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. (2017) (23)
Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. (2013) (23)
Patient Education Strategies to Improve Pneumococcal Vaccination Rates: Randomized Trial (2003) (23)
Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. (2008) (23)
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. (1996) (21)
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. (2021) (20)
Development and evaluation of a medication counseling workshop for physicians: can we improve on ‘take two pills and call me in the morning’? (2011) (20)
Estimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemia. (2011) (19)
Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment (2010) (19)
‘Trig‐onometry’: non‐high‐density lipoprotein cholesterol as a therapeutic target in dyslipidaemia (2011) (19)
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) (19)
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) (19)
Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease. (1997) (18)
An assessment of obesity among African-American women in an inner city primary care clinic. (2002) (18)
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. (2021) (18)
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. (2022) (18)
The Role of Omega-3 Fatty Acids in the Prevention of Coronary Heart Disease (2001) (17)
Omega 3 Fatty Acids (2006) (17)
Quality of care in African-American patients admitted for congestive heart failure at a university teaching hospital. (2006) (17)
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. (2022) (17)
Comparison of African-American patients with systolic heart failure versus preserved ejection fraction. (2006) (16)
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. (1994) (16)
Avoiding statin myopathy: understanding key drug interactions (2011) (16)
Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era (2003) (16)
Initiating statins in the elderly: the evolving challenge (2008) (15)
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results (2020) (14)
Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations (2017) (13)
2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia (13)
Prostate cancer screening in a low-literacy population: does informed decision making occur? (2005) (12)
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI (2022) (11)
Metabolic syndrome is associated with muscle symptoms among statin users. (2016) (11)
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. (2020) (10)
4-LB: Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES (2020) (10)
A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial (2012) (9)
Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients with Severe Hypertriglyceridemia and Changes Correlate with Increases in LDL-C: A Sub-analysis of the EVOLVE trial (2012) (9)
COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS (2020) (9)
Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention (2005) (9)
Chronic kidney disease and statins: Improving cardiovascular outcomes (2009) (9)
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. (2019) (9)
Omega-3 Fatty Acids for Cardiovascular Disease (2010) (8)
Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. (2012) (8)
Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia (2014) (8)
An Evidence-Based Approach to the Use of Combination Drug Therapy for Mixed Dyslipidemia (2006) (7)
Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies (2010) (7)
Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease. (2004) (6)
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT (2022) (6)
Self-Efficacy for Appropriate Medication Use Scale (2018) (6)
Dyslipidemia in Patients with Kidney Disease. (2021) (6)
Erratum: Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis (Current Atherosclerosis Reports (2011) 13 (474-483) DOI:10.1007/s11883-011-0210-3) (2012) (6)
Treating isolated low high-density lipoprotein cholesterol: prescient or premature? (2000) (6)
Statin Associated Muscle Symptoms: Characteristics of Patients and Recommendations by Providers* (2015) (6)
Adherence to Refills and Medications Scale (2017) (5)
ASMBS Guidelines/Statements, Part 2 Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA) 1 (2016) (5)
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) (5)
Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old (2011) (5)
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment (2022) (5)
Using Apolipoprotein B to Manage Dyslipidemia–Reply–I (2010) (4)
Achieving adherence to lipid-lowering regimens. (2013) (4)
Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. (2003) (4)
Safety considerations with fibrate therapy. Commentary (2007) (4)
Preventing Coronary Heart Disease in the Managed Care Era: Improving the Cost Effectiveness of Lipid-Lowering Therapy with HMG-CoA Reductase Inhibitors (1997) (4)
Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin (2013) (4)
Abstract 26: Scenario Analyses of Lifetime Cost-effectiveness of Icosapent Ethyl in REDUCE-IT (2020) (4)
Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Low-Density Lipoprotein Cholesterol: A Critical Review (2011) (3)
Combination use of statins and omega-3 fatty acids: an emerging therapy for combined hyperlipidemia (2006) (3)
Abstract 1189: Changes in the Prevalence of Abnormal Lipid Fractions among US Adults: Results from the National Health and Nutrition Examination Survey II, III, and 1999-2006 (2008) (3)
Abstract 57: Reduction in Ischemic Stroke With Icosapent Ethyl - Insights From REDUCE-IT (2021) (3)
Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: the primary care setting. (2006) (3)
JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. (2020) (3)
Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG (2020) (3)
Reaching National Cholesterol Education Program Goals: a managed care approach to improving hyperlipidemia disease management outcomes. Introduction. (2001) (3)
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. (2022) (3)
Lewis Dexter, MD 1910–1995 (1996) (3)
Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins (2017) (3)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. (2022) (3)
Abstract 10627: Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD (2021) (3)
REDUCE-IT: outcomes by baseline statin type (2020) (2)
Effect of baseline plasma fatty acids on eicosapentaenoic acid levels in individuals supplemented with α-linolenic acid (2009) (2)
Authors' reply to commentary entitled “EPA and DHA: Distinct yet essential n-3 fatty acids” (2012) (2)
Skeletal Muscle Disease as Noncardiac Cause of Cardiac Troponin T Elevation (2012) (2)
Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety (2010) (2)
Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. (2016) (2)
Abstract 3703: Trends in Lipid Fractions and Antidyslipidemic Use among US Adults: Findings from the National Health and Nutrition Examination Survey II, III, and 1999-2006 (2008) (2)
Fluvastatin, rhabdomyolysis, and myotoxicity. (2008) (2)
TEMPORARY REMOVAL: Lipids and Bariatric Procedures Part 1 of 2: Scientific Statement from the National Lipid Association (NLA), American Society for Metabolic and Bariatric Surgery (ASMBS), and Obesity Medicine Association (OMA) (2015) (2)
Quitting smoking: nicotine vs placebo gum. (1989) (1)
Abstract 12267: Efficacy and Safety of Alirocumab in Statin-Intolerant Patients Over 3 Years: Open-Label Extension of the ODYSSEY ALTERNATIVE Trial (2018) (1)
Abstract 15091: Significant Reductions in Both Adjudicated and Investigator-Reported Ischemic Events in REDUCE-IT (2020) (1)
REDUCING HIGH BLOOD CHOLESTEROL LEVELS WITH DRUGS. AUTHORS' REPLY (1991) (1)
Fenofibric Acid in Combination with Rosuvastatin 5, 10, or 20 Mg Improves the Atherogenic Lipid Profile in Patients ≥65 Years with Mixed Dyslipidemia (2009) (1)
Prevalence of the Metabolic Syndrome Defined by ATP III Guidelines in US Adults: Therapeutic Implications (2002) (1)
Development and Content Validation of a Patient-Reported Outcome Measure to Evaluate Statin Intolerance in the Real World (2016) (1)
Primary Prevention With Metoprolol in Patients With Hypertension (1988) (1)
ICOSAPENT ETHYL REDUCES CARDIOVASCULAR RISK SUBSTANTIALLY AND CONSISTENTLY REGARDLESS OF WAIST CIRCUMFERENCE (2022) (1)
Chronic hepatitis B. (1988) (1)
SIGNIFICANT CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL FROM REDUCE-IT (2020) (1)
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking (2022) (1)
Randomized Controlled Trial Enhance Pneumococcal Vaccination Rates : A Use of a Low-Literacy Patient Education Tool to Correction (1999) (1)
Fluvastatin, Rhabdomyolysis, and Myotoxicity–Reply–I (2008) (1)
Inhaled anticholinergics and the long-term treatment of chronic obstructive pulmonary disease: Weighing benefits and risks. (2009) (1)
Conclusions and recommendations from the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease (2010) (1)
Abstract 16486: Consistent Cost-effectiveness of Icosapent Ethyl Across Patient Profiles From REDUCE-IT (2020) (0)
REDUCTION IN HEART FAILURE WITH ICOSAPENT ETHYL: INSIGHTS FROM REDUCE-IT HF (2021) (0)
Abstract 216: Expert Review on Development of a Patient Measure for Statin Intolerance (2015) (0)
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology (2023) (0)
BENEFITS OF ICOSAPENT ETHYL IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME (ACS): REDUCE-IT ACS (2023) (0)
Improving the Cost Effectiveness of Lipid Lowering Therapy in Coronary Heart Disease Prevention (1998) (0)
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups (2020) (0)
Combination drug therapy for hyperlipidemia (1994) (0)
Su-S1:4 The muscle and statin safety (2006) (0)
A RANDOMIZED CONTROLLED TRIAL TO PROMOTE PHYSICIAN‐PATIENT DISCUSSION OF PROSTATE CANCER SCREENING.: 265 (2004) (0)
A double-blind controlled trial on the efficacy and safety of a new synthetic HMG-CoA reductase inhibitor, fluvastatin, with and without open-label niacin, in the treatment of hypercholesterolemia (1994) (0)
Abstract 15748: Alirocumab Efficacy and Safety by Race and Ethnicity: Analysis From Three ODYSSEY Phase 3 Trials (2017) (0)
Abstract 13202: Relationship Between Risk for Coronary Heart Disease and Serum Levels of Low-Density Lipoprotein Particles (2013) (0)
Evaluation of Statin Prescribing in Patients With an LDL ≥ 190 mg/dL in an Inner City Teaching Hospital (2017) (0)
Authors' response to letter by Anagnostis and Stevenson, "Is there a role for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?" (2019) (0)
REDUCE-IT: accumulation of data across prespecified interim analyses to final results (2020) (0)
Fewer LDL particles More LDL particles Cholesterol ester More apo B Less cardiovascular risk More cardiovascular risk (2011) (0)
Corrigendum to Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [Journal of Clinical Lipidology Volume 13, Issue 3, May–June 2019, Pages 374-392] (2022) (0)
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia (2016) (0)
Familial Hypercholesterolemia GENEtic evaluation of Minority patients with an LDL-C >190mg/dL: FH GENE-Minority Study (2019) (0)
COMPARISON OF CARDIOVASCULAR EVENTS BETWEEN PATIENTS ACHIEVING LOW-DENSITY LIPOPROTEIN PARTICLE TARGETS AND PATIENTS ACHIEVING LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGETS (2014) (0)
Coronary Artery Calcium scores in asymptomatic minority subjects with phenotypic Familial Hypercholesterolemia* (2019) (0)
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. (2023) (0)
Erratum to: Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis (2011) (0)
Reducing High Blood Cholesterol Levels With Drugs-Reply (1991) (0)
Using Apolipoprotein B to Manage Dyslipidemia. Authors' reply (2010) (0)
Reducing Readmissions—Destination or Journey? (2017) (0)
Incidence of Statin Intolerance in a Referral Lipid Clinic: Patient Characteristics and Response to Rechallenge* (2015) (0)
COMPARISON OF CARDIOVASCULAR EVENTS BETWEEN PATIENTS ACHIEVING LOW-DENSITY LIPOPROTEIN PARTICLE TARGETS AND PATIENTS ACHIEVING LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGETS IN A MIXED PRIMARY/SECONDARY PREVENTION SAMPLE (2015) (0)
Abstract 6280: Meta-Analysis of the Relationship between Non-High Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk (2008) (0)
TREATMENT PATTERN CHANGES IN HIGH RISK PATIENTS ON STATIN MONOTHERAPY IN A MANAGED CARE SETTING (2012) (0)
Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking (2022) (0)
Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis (2012) (0)
Comparative Effectiveness Of Rosuvastatin Versus Other Statins On Low-Density Lipoprotein Cholesterol (Ldl-C) Reduction In High Risk Patients (2014) (0)
LONG-TERM EFFICACY OF FENOFIBRIC ACID 135 MG IN COMBINATION WITH ROSUVASTATIN 20 MG IN PATIENTS WITH MIXED DYSLIPIDEMIA (2010) (0)
Abstract 13690: Clinical Benefits of Lowering Severely High Triglycerides on Cardiovascular Events, Pancreatitis, and Diabetes (2011) (0)
Formulary policy for cholesterol reduction (1991) (0)
Comparative Effectiveness of Rosuvastatin Versus Other Statins on Low-Density Lipoprotein Cholesterol (LDL-C) Reduction in Moderate-Risk Patients (2014) (0)
ICOSAPENT ETHYL REDUCES ISCHEMIC EVENTS IN PATIENTS WITH HIGH TRIGLYCERIDES AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: REDUCE-IT HIGH TG/LOW HDL-C ANALYSES (2021) (0)
Fluvastatin, Rhabdomyolysis, and Myotoxicity. Authors' reply (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Terry A. Jacobson?

Terry A. Jacobson is affiliated with the following schools:

Terry A. Jacobson's Academic­Influence.com Rankings

Terry A. Jacobson's Degrees

Similar Degrees You Can Earn

Why Is Terry A. Jacobson Influential?

Terry A. Jacobson's Published Works

Published Works

What Schools Are Affiliated With Terry A. Jacobson?

Terry A. Jacobson's AcademicInfluence.com Rankings